http://orcid.org/0000-0003-3491-1702
References
- Larney S, Peacock A, Mathers BM, et al. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39–49.
- Ciccarone D, Unick GJ, Cohen JK, et al. Nationwide increase in hospitalizations for heroin-related soft tissue infections: associations with structural market conditions. Drug Alcohol Depend. 2016;163:126–133.
- Kadri AN, Wilner B, Hernandez AV, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc. 2019;8(19):e012969.
- Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108:e1–e7.
- Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–239.
- Alpren C, Dawson EL, John B, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015-2018. Am J Public Health. 2020;110(1):37–44.
- Golden MR, Lechtenberg R, Glick SN, et al. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs – Seattle, Washington, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(15):344–349.
- Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Global Health. 2017;5(12):e1208–e1220.
- Kå M, Karlsson N, Discacciati A, et al. Significant decrease in injection risk behaviours among participants in a needle exchange program. Infect Dis. DOI:10.1080/23744235.2020.1727002
- Bluthenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. Aids. 2000;14(5):605–611.
- Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77(3):369–382.
- Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–248.
- Fernandes RM, Cary M, Duarte G, et al. Effectiveness of needle and syringe programmes in people who inject drugs – an overview of systematic reviews. BMC Public Health. 2017;17(1):309.
- Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. JAIDS J Acquir Immune Defic Syndr. 2016;73(3):323–331.
- Wester C, Sizemore L, McPheeters M, et al. Tennessee’s in-state vulnerability assessment for a “Rapid Dissemination of Human Immunodeficiency Virus or Hepatitis C Virus Infection” event utilizing data about the opioid epidemic. Clin Infect Dis. 2018;66(11):1722–1732.
- Tempalski B, Cooper HL, Friedman SR, et al. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy. 2008;19 (Suppl 1):47–58.
- Tempalski B, Flom PL, Friedman SR, et al. Social and political factors predicting the presence of syringe exchange programs in 96 US metropolitan areas. Am J Public Health. 2007;97(3):437–447.
- Tempalski B, Friedman R, Keem M, et al. NIMBY localism and national inequitable exclusion alliances: The case of syringe exchange programs in the United States. Geoforum. 2007;38(6):1250–1263.
- Des Jarlais DC, Nugent A, Solberg A, et al. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas – United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(48):1337–1341.
- Nguyen TQ, Weir BW, Des Jarlais DC, et al. Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment. AIDS Behav. 2014;18(11):2144–2155.
- Wilson DP, Donald B, Shattock AJ, et al. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5–S11.
- Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention (CDC). Prevention: opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631–635.